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Rat Stem-Cell Factor Induces Splenocytes Capable of
Regenerating the Thymus
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GARY S. ELLIOTT, R. WAYNE HENDREN,: RANDOLPH B. DEPRINCE,: and DALE L. GREINER
"Departments of Experimental Hematology and :Pharmaceutics and Drug Delivery, Amgen Inc., Amgen Center, 1840 Dehavilland Dr.,
Thousand Oaks, California 91320
University of Massachusetts Medical Center, Worcester, Massachusetts 01605
Cytokine regulation of prethymic T-lymphoid progenitor-cell proliferation and/or
differentiation has not been well-defined, although much is known of cytokine
regulation of hemopoietic stem- and progenitor-cell development. Here we use a
recently identified hemopoietic growth factor, stem-cell factor (SCF) (a form of the c-kit
ligand), and a transplant model of thymocyte regeneration to assess the effect of SCF on
the in vivo generation of prethymic, thymocyte progenitor-cell activity. We show that
164recombinant rat SCF (rrSCF administered to weanling rats selectively induces an
increase in thymocyte progenitor activity in the spleens of treated rats as compared to
rats treated with vehicle, polyethylene glycol (PEG)-conjugated rat albumin, or
recombinant human granulocyte colony-stimulating factor (rhG-CSF). These data
demonstrate that administration of SCF in vivo affects extrathymic-origin thymocyte
regenerating cells and may influence, directly or indirectly, early prethymic stages of T-
cell lymphopoiesis in addition to its known effect on early stages of myelopoiesis and
erythropoiesis.
KEYWORDS: Stem-cell factor, thymocytopoiesis, thymus, c-kit ligand, cytokines.
INTRODUCTION
Hemopoietic stem and progenitor cells play a
central role in the development of all blood-cell
lineages (Spangrude et al., 1991). During the past
10 years, much has been discerned concerning
the mechanisms by which hemopoietic stem- and
progenitor-cell development is regulated, par-
ticularly regarding the regulatory roles of cytok-
ines in myeloid lineage development (Clark and
Kamen, 1987). Less information has been forth-
coming about the possible role(s) of cytokines in
regulation of lymphoid stem- or progenitor-cell
development (Palacios and Pelkonen, 1988).
Recently, a glycoprotein was isolated and ident-
ified as a ligand for the tyrosine-kinase receptor
c-kit and has been variously termed c-kit-ligand
(Huang et al., 1990), mast cell-growth factor
(Williams et al., 1990), stem-cell factor (Zsebo et
al., 1990), and steel factor (Matsui et al., 1991).
*Corresponding author.
The gene for the c-kit ligand has been cloned and
the recombinant protein expressed in soluble
form (Anderson et al., 1990; Huang et al., 1990;
Martin et al., 1990; Langley et al., 1992).
Numerous in vitro studies have documented
that rrSCF164, one form of the c-kit ligand, affects
the development of a multitude of myelopoietic
(Andrews et al., 1990; Migliaccio et al., 1991),
erythropoietic (McNiece et al., 1991a), and certain
B-lymphoid progenitor cells (McNiece et al.,
1991b; Billips et al., 1992). Moreover, recent stud-
ies have shown that SCF administered in vivo
causes an increase in spleen- and marrow-
derived spleen colony-forming units (CFU-S) in
Steel-Dickie (S1/S1d) anemic mice (Bodine et al.,
1992). However, little is known of the effect that
in vivo administration of SCF may have on lym-
phopoiesis, particularly its possible effect on
early T-cell progenitor development.
In the present study, we have administered
rrSCF164 to rats and evaluated its capability to
influence the development of cells able to
repopulate the thymus in an irradiation-depen-
35
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dent model of thymocyte regeneration (Greiner
et al., 1984). We document that rrSCF164 causes an
increase in spleen cells that can repopulate the
thymus of adoptive recipients. These results
demonstrate that SCF can affect the development
of extrathymic-origin stem/progenitor cells able
to reconstitute the thymus in addition to its
known effect on myeloid (Andrews et al., 1990;
Migliaccio et al., 1991), erythroid (McNiece et al.,
1991a), and B-lymphoid progenitor cells
(McNiece et al., 1991b; Billips et al., 1992).
RESULTS
rrSCF164 was administered daily for 7 days in all
subsequent experiments.
We designed the next series of experiments to
address whether the increase in lymphoid cells
(in particular T-lymphoid cells) in the peripheral
blood may be associated with an increase in pro-
genitor cells important for the development of
the T-lymphocyte lineage. Spleen and bone mar-
row from rats treated for 7 days with either
rrSCF164 or vehicle were tested for quantitative
differences in thymocyte progenitor-cell activity.
In this assay system, graded numbers of cells
were adoptively transferred into irradiated, his-
tocompatible, RT-7 (a polymorphic determinant
on the rat leukocyte common antigen that is pre-
In initial experiments, a factor dose (2.5-500 t
g/kg) and kinetic (days 0-29) analysis of the
hematological response of rats to administration
of rrSCF164 were determined. An optimal increase
in peripheral blood leukocytes was observed
between days 4 and 18 when using a dose of
500 tg/kg of rrSCF164 (Fig. 1). Increases in spleen
and peripheral blood leukocyte numbers were
observed on day 7 of treatment (Table 1). Spleen ,,
weight and cellularity increased approximately rO
1.5- and 1.4-fold, respectively (Table 1). Increases
were apparent in all hemopoietic lineages,
including granulocytes, lymphocytes (B and T
cells), and monocytes (data not shown).
Although bone marrow-cell numbers were unaf-
fected by this tre.atment (Table 1), cytological
analysis revealed a distinct myeloid hyperplasia
in the marrow as a result of rrSCF164 treatment
(data not shown). No significant changes in thy-
mus cellularity were observed.
These data suggest that in vivo administration
of SCF causes hematological changes in both the
peripheral and central hemopoietic tissues. The
underlying mechanism for these hematological
changes are not fully understood, but recent evi-
dence has shown that SCF alone or in combi-
nation with other hemopoietically active factors
causes the in vitro proliferation of myeloid and B-
lymphoid progenitor cells and the in vivo pro-
liferation of certain types of myeloid
stem/progenitor cells identified as CFU-S
(Andrews et al., 1990; McNiece et al., 1991a,
1991b; Billips et al., 1992; Bodine et al., 1992).
Thus, the increase in mature end-stage progeny
as a result of SCF treatment in vivo may be
directly related to an increase in less mature pro-
genitor cells. Based on our results, 500 tg/kg of
15ooo
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FIGURE 1. White blood cell (WBC) absolute numbers in
M520 rats treated with varying dosages of rrSCFa6 for 29 days.
Data are presented as the mean+S.D, of three individual rats.
TABLE
Cell Number in Lymphohemopoietic Tissues following Stem-
Cell Factor Administration
Treatment Spleen Bone marrow Peripheral
(X106) (X106) blood
(cells//lxl03)
Vehicle 735+45 59+5 9.6+0.5
rrSCF164 1019+116 61+20 17.7+5.1
rhG-CSF 906+74 106+7.6 20.5+4.2
"Each data point represents the mean+standard deviation (S.D.) of eight
individual rats from three separate experiments with the exception of the values for
rhG-CSF, which the mean+S.D, of three individual rats. All data obtained
from rats treated for 7 days. Spleen values represent the number of cells per organ
and bone values represent the number of cells per femur.
bp<0.01 vehicle-treated values.
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sent on all thymocytes) alloantigen disparate
recipients (Hale et al., 1987; Sunderland et al.,
1979; Thomas et al., 1985). The percentage and
number of donor-origin thymocytes, hence thym-
ocyte progenitor activity of the donor inoculum,
were determined by flow cytometric analysis of
donor alloantigen RT-7/ thymocytes in the recipi-
ents. Because the kinetics of thymus regeneration
in rats differs among tissue sources of progeni-
tors, it was important to compare several time
points of regeneration and transplant cell doses
in this model system. For example, the
exponential phase of thymus regeneration
resulting from a bone marrow transplant occurs
between day 12-20 posttransplantation, whereas
that due to similar numbers of spleen cells occurs
later post-transplantation (Greiner et al., 1984).
Thymus repopulation by bone marrow cells
was unaffected by rrSCF164-treatment of donors
when assayed on either day 18 or 27 after trans-
plantation (Tables 2 and 3, respectively). As
shown in Table 2, donor-thymocyte regeneration
was proportional to the number of bone marrow
cells from vehicle-treated rats transplanted when
assayed 18 days posttransplant. No increase or
decrease in regeneration was detected when bone
marrow cells from rrSCF164-treated rats were
similarly transplanted. However, as predicted
from previous studies (Greiner et al., 1984), thy-
mus regeneration resulting from bone marrow
cells was not proportiqnal to transplant cell doses
when assayed 27 days posttransplantation (Table
3) (a time during regeneration when donor thym-
ocyte numbers have plateaued). Furthermore, no
change in thymocyte regeneration was observed
when recipients of bone marrow cells from
rrSCF164-treated rats were analyzed at day 27
(Table 3).
Recipients of spleen cells from rrSCF164-treated
rats had greater thymus regeneration than recipi-
ents of spleen cells from vehicle-treated rats, but
this result was most evident after 27 to 28 days
posttransplantation. Recipients of spleen cells
from rrSCF164-treated rats analyzed on day 18 dis-
played no significant differences when compared
with vehicle-treated rats (Table 2). In contrast,
recipients of spleen cells from rrSCF64-treated
rats analyzed either on day 27, 28, or 29 showed
significantly (p<0.05) higher regeneration
capacity than spleen cells from donors treated
similarly with vehicle (Table 3, Table 4, and Fig.
2).
In an additional series of experiments, rats
were treated separately with either rat albumin
(conjugated with PEG), rrSCF164 or rhGCSF for 7
days and spleen cells from each of these donors
were assayed for thymocyte progenitor activity.
Rats treated with albumin conjugated with PEG
were similar to vehicle-treated rats in that no per-
ipheral blood, spleen, or bone marrow hematol-
ogical changes were observed (data not shown).
Furthermore, no change was noted in the ability
of splenocytes from PEG-conjugated albumin-
treated rats to cause donor-origin thymus regen-
eration when compared with vehicle-treated
spleen cells from several separate experiments
TABLE 2
Thymus Repopulation Capacity of Hemopoietic Tissues from Stem-Cell Factor, or Vehicle-Treated Rats on Day 18
Treatment Donor Cells Thymocytes Donor-origin
tissue transferred (xl06) thymocytes
(x107) (xl0)
Vehicle Spleen 1.0 387+227 7.7+6.9
Vehicle Spleen 2.5 440+72 28.5+14.4
rrSCF164 Spleen 1.0 531+120 18.1--+5.4b
rrSCF164 Spleen 2.5 376+101 33.3-+25.3
Vehicle Bone marrow 0.5 500-+195 20.6-+10.3
Vehicle Bone marrow 1.0 577+297 37.5-+17.1
Vehicle Bone marrow 2.0 518-+80 115.0+222.0
Vehicle Bone marrow 4.0 552+89 80.9-+79.8
rrSCF64 Bone marrow 0.5 611+187 27.7-+23.6
rrSCF64 Bone marrow 1.0 443-+89 17.3+6.9
rrSCF64 Bone marrow 2.0 499+170 71.7+13.0
rrSCF6a Bone marrow 4.0 584-+176 96.7-+26.4
Each group represents the meanS:standard deviation of four individual recipients analyzed day 18 posttransplantation.
bNot significantly different from vehicle-treated control values.
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TABLE 3
Thymus Repopulation Capacity of Hemopoietic Tissues from Stem-Cell Factor, or Vehicle-Treated Rats on Day 27
Treatment Donor Cells Thymocytes Donor-origin
tissue transferred (xl06) thymocytes
(10 (xl0
Vehicle Spleen 2.5 191+73 33.2+5.6
Vehicle Spleen 5.0 200+58 69.6+32.2
rrSCF164 Spleen 2.5 159+53 86.9+12.5
rrSCF164 Spleen 5.0 238+85 170.4+29.6
Vehicle Bone marrow 1.0 199+87 136.9+24.8
Vehicle Bone marrow 2.5 184+21 136.8+10.9
Vehicle Bone marrow 5.0 180+46 111.4+34.4
rrSCFTM Bone marrow 1.0 222+101 130.1+37.6
rrSCF64 Bone marrow 2.5 204+56 117.5+28.8
rrSCFTM Bone marrow 5.0 178+60 113.5+19.5
aEach group represents the mean+standard deviation of to 10 individual recipients analyzed day 27 posttransplantation.
bp<0.05 vehicle-treated values.
CNot significantly different from vehicle-treated control values.
TABLE 4
Thymus Repopulation Capacity of Various Rat Spleen-Cell
Populations
Treatment Cells Thymocytes Donor-origin
transferred (106 thymocytes
(xl07) (xl0)
Experiment
Vehicle 1.0 518+53 6.3+4.7
Vehicle 2.5 492+103 15.9+11.3
Vehicle 5.0 484+86 23.0+7.1
rrSCFTM 1.0 543+132 13.6+5.0
rrSCF164 2.5 490+72 46.2+5.4b
rrSCF64 5.0 499+34 72.6+3.0
Lin- rrSCFTM 0.1’ 515+30 12.3+2.6
Lin- rrSCF64 0.5 536+74 32.0+16.0
Lin- rrSCF164 1.0 544+79 69.0+27.5
Experiment II
AlbuminPE 1.0 746+211 12.2+3.2
AlbuminPE 2.5 709+125 12.1+3.3
rhG-CSF 1.0 616+100 7.3+2.5
rhG-CSF 2.5 710+119 9.0+5.8
rrSCF64 1.0 801+153 30.0+19.6
rrSCFTM 2.5 774+45 55.4+51.7
aEach group represents the mean+standard deviation of four individual recipients
analyzed day 27 in Experiment and day 28 in Experiment II.
bp<0.005.
CNot significantly different from vehicle-treated control values obtained in two
separate experiments.
dAlthough rrSCF regeneration values in Experiment II not significant, when
compared with the recipients of albumin-treated rat splenocytes, retrospectively
compared with vehicle-treated controls, two of four recipients in each cell dose
displayed high levels of regeneration.
Thus, in the 1.0107 cell dose, donor cell levels of 53106 and 39106 and
in the 2.5107 cell dose with donor cell levels of 118x106 and 78106
(Table 4). An increase in numbers of spleen, bone
marrow, and peripheral blood nucleated cells
was observed in rats treated with rhGCSF (Table
1). This was primarily due to an increase in
mature polymorphonuclear granulocytes (data
not shown). No differences were detected in the
ability of spleen cells from rhGCSF-treated rats to
cause donor-origin thymus regeneration when
compared with splenocytes from rats treated
with rat albumin conjugated with PEG (Table 4).
Recipients similarly transplanted with spleno-
cytes from rats treated with rrSCFTM displayed
increases in thymocyte regeneration compared
with controls confirming our other results (Table
4).
The thymus repopulating cell(s) in the spleen
of rrSCF164-treated rats was found to be lympho-
cyte-lineage negative (Lin-). Splenocytes of
164rrSCF -treated rats were depleted of CD4, CD8,
and surface immunoglobulin (sIg)-bearing cells
with immunomagnetic beads. We recovered
approximately 20% of the starting spleen-cell
population following the enrichment procedure.
When transplanted, the Lin- cells displayed an
approximately five-fold enrichment in prothym-
ocyte activity. Thus, lx10 Lin-rrSCF164-treated
splenocytes caused the same level of thymus
regeneration that was observed following trans-
plantation of 5x10 unfractionated rrSCF164-
treated splenocytes (Table 4). In a separate analy-
sis, the Lin-cell population was found to have
-<10% contaminating Lin/ cell types.
Finally, we determined that the increase in
spleen-origin thymus repopulating cell activity
was a function of increasing doses of rrSCFTM
(Fig. 2). An increase in donor-origin thymocytes
of spleen-cell recipients from donors treated with
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FIGURE 2. Thymocyte regeneration following i.v. adoptive
transfer of M520 (RT-7.1) spleen cells (25x106/rat) to BUF (RT-
7.2) recipients. M520 rats were treated with varying dosages of
rrSCF164 or vehicle for 7 days at which time the splenocytes
were transferred to irradiated BUF recipients. BUF recipients
were analyzed on day 29 after transplantation. Data are
presented as the mean+S.D, of RT-7.1 (donor-origin)
thymocytes from four individual recipients.
100 or 500/g/kg of rrSCF164 was observed (Fig.
2).
V19:EM02061096\FL1\
M520 RAT A
VIS:EM02061001\FL1\
RAT
DISCUSSION
We have used the ability of a cell to generate
donor-origin thymocytes in an adoptive recipient
as a functional definition of thymocyte progeni-
tor activity. Thymocyte progenitor activity has
been detected previously in bone marrow-,
spleen-, blood-, and thymus-cell populations, but
the factors that regulate the growth and differen-
tiation of prethymic T-lymphocyte progenitor
cells are not well-understood (Greiner et al.,
1984; Goldschneider et al., 1986; Palacios and Pel-
konen, 1988). Furthermore, it is unclear as to
whether thymus repopulating activity is due to
pluripotent hemopoietic stem cells, a common T-
and B-lymphoid stem cell, or a restricted pro-
genitor cell committed only to the T lineage.
We demonstrate in the present study that a
population of splenic-origin thymus repopulat-
ing cells is induced by in vivo treatment with
vIg:EM02061218\FL1\
BUF RAT RECIPIE T
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C
FIGURE 3. Representative fluorescence histogram profiles of
NDS58 (RT-7.1) (shaded curve) and HIS41 (RT-7.2) (unshaded
curve) reactivity on (A) M520 rat thymocytes, (B) BUF rat
thymocytes, and (C) thymocytes from a BUF rat reconstituted
27 days previously with 50x106 M520 splenocytes. In (C), 49%
of the thymocytes were RT-7.1 /, M520-origin, NDS58 reactive
thymocytes and 53% of the thymocytes were RT-7.2/, BUF-
origin, HIS41 reactive thymocytes.
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rrSCFTM. Thus, we show that spleen-origin thym-
ocyte progenitor activity was increased in rats
administered rrSCFTM in vivo for 7 days. In con-
trast, bone marrow-origin thymocyte progenitor
activity was not increased by similar treatment.
Our data indicate that elevated levels of donor-
origin thymocytes due to spleen-cell transplants
were most evident on days 27-28 posttransplan-
tation. This is in contrast to the kinetics of regen-
eration by bone marrow progenitors that reach
plateau levels of regeneration by day 20 (Greiner
et al., 1984). This apparent difference in the kin-
etics of thymocytopoiesis may be due in part to
differences in the relative numbers of thymus
repopulating cells in the spleen versus the bone
marrow, to differences in thymus colonizing
ability of spleen cells versus bone marrow cells,
and/or to differences in the developmental stage
of spleen versus bone marrow progenitors.
Previous reports have shown that SCF either
alone or in combination with other hemopoietic
growth factors or interleukins stimulates primi-
tive stem- and progenitor-cell populations
important for the production of macrophages,
granulocytes, erythrocytes, and B-lymphoic pro-
genitor cells (Andrews et al., 1990; McNiece et al.,
1991a, 1991b; Migliaccio et al., 1991; Billips et al.,
1992; Bodine et al., 1992). Moreover, SCF has
been shown to stimulate the in vitro growth of
enriched marrow-derived stem-cell populations
(Bernstein et al., 1991; de Vries et al., 1991;
Williams et al., 1992). Our results would suggest
that SCF stimulates the proliferation and/or dif-
ferentiation of a primitive cell in the spleen that
has the capacity of migrating to the thymus and
generating thymocytes. It is not clear whether the
cell population affected in the spleen is dis-
tinguishable from a pluripotential hemopoietic
stem cell capable of generating all hemopoietic
lineages (Spangrude et al., 1989; Jordan et al.,
1990; Spangrude and Scollay, 1990). However,
our lineage-depletion studies as well as pre-
viously published studies in which mature T-
lymphocytes were transplanted indicate that thy-
mus reconstitution was most likely not the result
of thymus colonization by nonactivated, mature,
peripheral T cells (Goldschneider et al., 1986;
Agus et al., 1991).
A more trivial explan.ation of our results may
be that rrSCFTM causes shunting of thymus re-
populating cells from the marrow to the spleen
via the vascular system. Administration of other
hemopoietically active cytokines, such as rhG-
CSF, has been shown to induce shunting of stem
and progenitor cells to the peripheral blood from
the bone marrow (Molineux et al., 1990). In our
model system, administration of rhG-CSF to rats
caused increased levels of granulocytes in per-
ipheral blood, spleen, or bone marrow. However,
rhG-CSF did not cause an apparent shunting of
thymus repopulating cells to the spleen from the
bone marrow because spleen thymocyte progeni-
tor activity levels in these rhG-CSF-treated ani-
mals were not different from albumin-treated
controls or vehicle-treated controls from other
experiments. Additionally, thymocyte progenitor
activity levels in the bone marrow of rrSCFTM
treated rats did not decrease but remained stable
following treatment. In preliminary experiments,
we have observed that peripheral blood
nucleated cells from rrSCFTM treated rats did not
differ in thymocyte progenitor activity compared
with controls (Medlock and Housman, unpub-
lished observations) further suggesting that the
increase in thymus repopulating cells in the
spleen was not due to shunting of such cells from
the bone marrow via the vascular system.
Another, less likely mechanism that might
explain our results is that the PEG conjugated to
the rrSCF164 was the contributing factor in stimu-
lating the increase in spleen-origin thymocyte
progenitor activity. Rats treated with 500/tg/kg
of PEG-conjugated rat albumin displayed no
change in the levels of thymocyte progenitor
activity when compared to vehicle-treated rats,
suggesting that PEG itself did not induce splenic
thymocyte progenitor activity.
In contrast to the previously mentioned mech-
anisms, rrSCFTM may instead induce the develop-
ment of a splenic accessory cell that cocolonizes
the thymus along with spleen-derived thymus
repopulating cells, enhancing their thymocyte
regenerating ability. This putative accessory cell,
although it has not been physically separated
from a thymocyte progenitor cell, appears to be
of myeloid, not lymphoid, origin or may derive
from hemopoietic stem-cell differentiation in the
thymus (Fowlkes and Pardell, 1989; Spangrude
and Scollay, 1990). Furthermore, in vitro (Deluca,
1986; Deluca and Misel, 1986) and in vivo
(Greiner et al., 1986; Komschlies et al., 1987;
Hayes et al., 1992) thymic repopulation studies
have suggested that this accessory cell may be a
rate-limiting factor in thymocyte repopulation.
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Thus, rrSCFTM may affect a myeloid accessory
cell, rather than a lymphoid progenitor cell,
resulting in increased accessory cell activity and
enhanced thymocyte repopulation.
Although thymocyte progenitor activity has
been identified in many tissues throughout the
body (Goldschneider et al., 1986), the primary
source, or at least the source with the largest
population, is the bone marrow in the adult
(Kadish and Basch, 1986; Greiner et al., 1984;
Goldschneider et al., 1986; Katsura et al., 1986).
However, we have observed that the primary site
of rrSCFTM action on this type of cell activity is
selective to the spleen, an apparently secondary
source of thymocyte progenitor activity in the rat
(Greiner et al., 1984; Goldschneider et al., 1986).
This apparent discrepancy might be explained by
the simple fact that PEG-conjugated rrSCFTM was
unable to stimulate the bone marrow perhaps as
a result of the inability of PEG-conjugated
rrSCFTM to enter the bone marrow microenviron-
ment. This seems unlikely because we have
observed that, although bone marrow cellular
numbers do not change as a result of treatment,
there is a bone marrow cytological change with
elevated levels of morphologically detectable
myeloid precursor cells. Alternatively, the
increase in spleen thymocyte progenitor activity
may indirectly suggest that the bone marrow and
spleen thymus repopulating cells might be devel-
opmentally distinct ty,pes of hemolymphopoietic
cells. Thus, rrSCFTM may act on one type of
thymus repopulating cell but not the other.
Abramson et al. (1977) were the first to demon-
strate that T-restricted stem progenitor cells may
exist in the bone marrow using radiation-induced
chromosomal aberrations as a clonal marker.
Dick et al. (1985) detected similar cells using
insertion of a selectable gene as a clonal marker.
Moreover, it is certain that pluripotent hemopo-
ietic stem cells are able to reconstitute all blood
lineages including T cells that are generated in
the thymus (Jordan et al., 1990). Indeed, certain
studies have suggested that prethymic-origin
thymus repopulating cells may be separated into
two distinct cell phenotypes in the mouse
(Spangrude et al., 1989). The first is a Thylc,
Lin-, Sca-1/ cell type similar to hemopoietic stem
cells, and the second is ThylL, Lin/, Scal/, which
contains no hemopoietic st6m-cell activity. How-
ever, the demonstration of two separate popu-
lations of thymus repopulating cells in rat bone
marrow and/or spleen must await cellular purifi-
cation of thymocyte progenitor cells from each
source with subsequent comparison of their
respective antigenic and functional phenotypes.
In conclusion, we have detected an additional
biological activity of rrSCF164 in which thymocyte
progenitor activity is selectively altered in the
spleens of rrSCF164-treated rats. Future studies
will be directed toward the isolation and charac-
terization of these spleen-derived thymocyte pro-
genitor cells for the purpose of comparing and
contrasting their physical and functional proper-
ties with those present in the bone marrow.
MATERIALS AND METHODS
Growth Factors
Recombinant rrSCFTM and rhG-CSF were purified
after expression in Escherichia coli, as described
previously (Souza et al., 1986; Langley et al.,
1992). Methoxypolyethylene glycol (MW=6000)
was obtained from Union Carbide Chemicals and
Plastic Company (South Charleston, WV) and
activated as previously described (Veronese et
al., 1989). PEG-conjugated SCF, containing two to
three PEG strands per SCF subunit, was prepared
by an adaptation of a previously published
method (Tanaka et al., 1991) and used because
previous studies have shown that PEG improves
the stability of other cytokines in vivo (Katre et
al., 1986; Tanaka et al., 1991). PEG-conjugated rat
albumin was prepared similarly.
rrSCF164 Treatment Protocol
In initial experiments, factor dose and kinetic
responses of rats to rrSCF164 Were performed. In
most subsequent experiments, 4- to 6-week-old
M520 rats (NCI, Frederick, MD) were treated
daily with 500/g/kg of rrSCFTM or vehicle
(buffered saline with 1% fetal bovine serum) sub-
cutaneously for 7 days. In certain experiments,
M520 rats were treated with either 500tg/kg
PEG-conjugated albumin or 50/g/kg of rhG-
CSF. On day 7, blood, spleen, and bone marrow
cells were collected and analyzed.
Cell Suspensions
Peripheral blood was collected using EDTA as an
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anticoagulant. Bone marrow suspensions were
prepared by flushing the femur with medium
(RPMI 1640) and spleen-cell suspensions were
made by extrusion of the spleens through a 50-
mesh wire screen into medium. Cell counts were
performed using a Coulter Counter Channelizer
(Hialeah, FL). In certain experiments, blood was
collected on days 4, 7, 11, 14, 18, 25, and 29 of fac-
tor treatment and analyzed by flow cytometry
and Coulter analysis. All bone marrow-cell trans-
plants were done by intravenous injection.
Thymi from recipients were removed at various
times after transplantation and cell suspensions
prepared. Absolute nucleated cell numbers were
determined by Coulter analysis.
Irradiation
Male BUF (Harlan) (alloantigen-RT7.2/) rats aged
4-6 weeks were whole body irradiated with 7.5
Gy using a 137Cs source (Gammacell 40, Atomic
Energy of Canada, Ltd.) 4-6 hours prior to trans-
plantation with M520 (alloantigen-RT7.1/)
tissues.
mately 49% of this regenerating thymus (Fig. 3).
The data comparing rrSCF164 treatment with
vehicle treatment in Tables 2, 3, and 4, and Fig. 2
have been reproduced in nine separate exper-
iments. All statistics have been performed using
the student’s "T" test for grouped data.
Lin--Cell Preparation
Lin- cells were prepared by labeling spleen cells
from rrSCF164-treated rats with mouse antibodies
to rat CD4 (clone W3/25), CD8 (clone OX8),
(Accurate Chemical and Scientific Corp.,
Westbury, NY) and sIg (Southern Biotechnology
Associates, Birmingham, AL). Labeled cells were
reacted and depleted twice with immunomag-
netic beads conjugated with sheep anti-mouse Ig
(Dynal Corp., Oslo, Norway). Nonadherent cells
were recovered, washed twice, and suspended at
the appropriate concentration for i.v., injection.
Lin- cells were assayed for contaminating CD4,
CD8, and sIg-bearing cells by staining the Lin-
cells with a FITC-conjugated goat anti-mouse Ig
and analyzed on the FACScan.
Antibody Labeling and Flow Cytometry
Analysis
Each thymus-cell suspension was incubated with
antibodies to the RT7.1 alloantigen (clone NDS 58
or BC84) or RT7.2 alloantigen (clone HIS 41,
Bioproducts for Science, Indianapolis, IN) and
developed for fluorescence analysis with goat
anti-rat Ig FITC or goat anti-mouse Ig FITC,
respectively. Red blood cells were removed fol-
lowing staining using lysing buffer according to
the manufacturer’s protocol (Becton Dickinson,
Milpitas, CA). Labeled cells were fixed in 1%
buffered formalin and analyzed with a FACScan
cell analysis system (Becton Dickinson) within
24-48 hr. The percentage of positive cells for each
antibody was determined from histogram pro-
files and the absolute number of donor (RT7.1 /)
cells was determined by the following formula:
No. donor cells=% NDS58/ cells-% rat Ig/ cellsx
absolute number of thymocytes. As shown,
NDS58 labels 100% of M520=origin thymocytes
and 0% of BUF-origin thymocytes, and HIS41
labels 100% of BUF-origin thymocytes and 0% of
M520-origin thymocyte (Fig. 3). A representa-
tive BUF recipient of M520 splenocytes is shown
that indicates that NDS58 discriminates approxi-
NOTE ADDED IN PROOF
In a recent study by Chervenak et al., 1992, J.
Immunol. 149: 2851-2856, it has been shown that
c-kit ligand (MGF) induces the expansion of a
population of thymocyte progenitor cells when
cultured in vitro with MGF. This in vitro evidence
confirms and extends our in vivo evidence
reported herein.
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